Kexing Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	614.04	650.43	554.56	568.8	785.38	877.62
Cash & Short-Term Investments	628.04	650.43	554.56	568.8	785.38	877.62
Cash Growth	8.98%	17.29%	-2.50%	-27.58%	-10.51%	-20.41%
Accounts Receivable	658.84	727.3	563.82	342.04	387.44	382.62
Other Receivables	20.69	20.12	15.9	4.45	3.25	2.84
Receivables	679.53	747.43	579.72	346.49	390.69	385.46
Inventory	155.36	139.22	141.81	191.36	208.18	172.16
Other Current Assets	90.27	70.28	11.72	26.97	27.06	25.57
Total Current Assets	1,553	1,607	1,288	1,134	1,411	1,461
Property, Plant & Equipment	1,094	1,099	1,177	1,200	1,053	936.24
Long-Term Investments	308.86	311.58	203.41	245.32	15	247.46
Other Intangible Assets	222.67	229.48	225.14	158.72	165.82	26.96
Long-Term Accounts Receivable	-	-	-	-	0.31	-
Long-Term Deferred Tax Assets	129.06	120.71	117.22	133.98	80.83	12.1
Long-Term Deferred Charges	112.58	97.23	50.37	3.08	-	21.82
Other Long-Term Assets	69.94	68.09	101.02	156.61	438.91	123.64
Total Assets	3,490	3,534	3,162	3,031	3,165	2,829
Accounts Payable	195.35	229.18	71.91	56.02	67.78	65.73
Accrued Expenses	35.48	35.7	112.98	84.14	92.89	97.63
Short-Term Debt	176.61	162.83	269.12	120.7	162.69	276.26
Current Portion of Long-Term Debt	540.18	504.41	313.25	275.03	51.78	-
Current Portion of Leases	-	-	12.45	6.7	19.87	18.39
Current Income Taxes Payable	8.9	13.26	-	-	-	-
Current Unearned Revenue	16.43	12.92	9.78	20.44	17.99	7.16
Other Current Liabilities	64.21	62.96	96.91	106.97	126.36	138.44
Total Current Liabilities	1,037	1,021	886.4	669.99	539.37	603.61
Long-Term Debt	685.11	727.7	611.18	695.84	779.23	263.37
Long-Term Leases	8.27	1.82	14.78	17.79	24.96	43.25
Long-Term Unearned Revenue	11.13	11.28	3.15	5.32	0.75	0.99
Long-Term Deferred Tax Liabilities	20.13	18.99	7.48	11.36	14.55	7.12
Total Liabilities	1,762	1,781	1,523	1,400	1,359	918.34
Common Stock	201.26	201.26	199.64	199.2	198.7	198.7
Additional Paid-In Capital	1,313	1,313	1,288	1,282	1,274	1,266
Retained Earnings	298.64	316.57	176.78	145.3	335.59	445.76
Treasury Stock	-86.18	-80.36	-31.12	-	-	-
Comprehensive Income & Other	1.2	0.93	1.11	-0.01	-	-
Total Common Equity	1,728	1,751	1,635	1,626	1,808	1,911
Minority Interest	0.9	1.51	4.34	4.77	-2.53	-
Shareholders' Equity	1,729	1,753	1,639	1,631	1,806	1,911
Total Liabilities & Equity	3,490	3,534	3,162	3,031	3,165	2,829
Total Debt	1,410	1,397	1,221	1,116	1,039	601.27
Net Cash (Debt)	-782.12	-746.33	-666.22	-547.26	-253.16	276.35
Net Cash Growth	-	-	-	-	-	-64.88%
Net Cash Per Share	-3.96	-3.79	-3.39	-2.76	-1.26	1.40
Filing Date Shares Outstanding	199.3	191.63	197.76	199.2	198.7	198.7
Total Common Shares Outstanding	199.3	191.63	197.76	199.2	198.7	198.7
Working Capital	516.05	586.1	401.41	463.63	871.94	857.2
Book Value Per Share	8.67	9.14	8.27	8.16	9.10	9.62
Tangible Book Value	1,505	1,522	1,410	1,467	1,643	1,884
Tangible Book Value Per Share	7.55	7.94	7.13	7.37	8.27	9.48
Buildings	-	-	754.25	662.95	609.2	361.78
Machinery	-	-	514.22	370.42	326.3	243.82
Construction In Progress	-	-	176.82	372.56	256.57	428.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.